<?php
include_once('../../includes/inc.php');
htmlHeader(array("title"=>"","metaDesc"=>"Dedicated to improving cancer outcomes via liquid biopsies.","preLoader"=>"0"));
?>
<div class="main-container">
    <section class="image-bg overlay parallax pt40 pb40 pt-xs-80 pb-xs-80">
        <div class="background-image-holder">
            <img alt="image" class="background-image overlay" src="/img/lungTumor.jpg">
        </div>

        <div class="container">
            <div class="row">
                <h1>New Product Title</h1>
            </div>

        </div>
    </section>
    <section>
        <div class="container">
            <div class="row">
                <div class="col-sm-4 col-md-4">
                    <h2 class="color-primary">Something</h2>
                    <hr>
                    <table class="table table-striped mutTable">
                        <thead>
                            <tr>
                                <th>SNV/Indel</th>
                                <th>Fusions</th>
                                <th>CNV</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="gene">AKT1<br>ALK<br>B2M<br>BRAF<br>EGFR<br>ERBB2
                                    (HER2)<br>FGFR2<br>FGFR3<br>KEAP1<br>KRAS<br>MAP2K1
                                    (MEK1)<br>MET<br>NRAS<br>PIK3CA<br>RET<br>ROS1<br>STK11</td>
                                <td class="gene">ALK<br>EGFR<br>FGFR2<br>FGFR3<br>NTRK1<br>RET<br>ROS1</td>
                                <td class="gene">B2M<br>EGFR<br>ERBB2
                                    (HER2)<br>FGFR1</br>KRAS<br>MET<br>MYC<br>NTRK1<br>PIK3CA<br>PTEN<br>RICTOR<br>STK11
                                </td>
                            </tr>
                        </tbody>
                    </table>
                </div>
                <div class="col-sm-6 col-md-6 col-md-offset-1">
                    <h2 class="color-primary">Something 2</h2>
                    <hr>
                    <table class="table table-striped mutTable">
                        <thead>
                            <tr>
                                <th>Biomarker</th>
                                <th>Therapy</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>exon 19 deletion<br>exon 21 L858R</td>
                                <td>Gilotrif® (afatinib)<br>Tarceva&reg; (erlotinib)<br>Vizimpro&reg;
                                    (dacomitinib)<br>Iressa&reg; (gefitinib)<br>Tagrisso&reg; (osimertinib)</td>
                            </tr>
                            <tr>
                                <td>EGFR S768I, L861Q, and/or G719X</td>
                                <td>Gilotrif&reg; (afatinib)</td>
                            </tr>
                            <tr>
                                <td>ALK fusions</td>
                                <td>Alecensa&reg; (alectinib)<br>Alunbrig&reg; (brigatinib)<br>Lorbrena&reg;
                                    (lorlatinib)<br>Xalkori&reg; (crizotinib)<br>Zykadia&reg;(ceritinib)
                                </td>
                            </tr>
                            <tr>
                                <td>ROS1 fusions</td>
                                <td>Xalkori&reg; (crizotinib)<br>Zykadia&reg;(ceritinib)<br>Rozlytrek&reg; (entrectinib)
                                </td>
                            </tr>
                            <tr>
                                <td>NTRK1 fusions</td>
                                <td>Vitrakvi&reg; (larotrectinib)<br>Rozlytrek&reg; (entrectinib)</td>
                            </tr>
                            <tr>
                                <td>BRAF V600E</td>
                                <td>Tafinlar&reg; (dabrafenib) in combination with Mekinist® (trametinib)</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
        </div>
    </section>
    <section class="page-title page-title-3 image-bg overlay parallax">
        <div class="background-image-holder">
            <img alt="Background Image" class="background-image" src="/img/bloodcells.jpg">
        </div>
        <div class="container">
            <div class="row">
                <div class="col-sm-12 text-center">
                    <h3 class="uppercase mb0">Something 3</h3>
                </div>
            </div>

        </div>
    </section>
    <section>
        <div class="container">
            <div class="row mb0 mb-xs-24">
                <div class="col-sm-6">
                    <h2 class="color-primary">Clinical Utility</h2>
                    <p>She sat in the darkened room waiting. It was now a standoff. He had the power to put her in the
                        room, but not the power to make her repent. It wasn't fair and no matter how long she had to
                        endure the darkness, she wouldn't change her attitude. At three years old, Sandy's stubborn
                        personality had already bloomed into full view.</p>
                    <p>"Do Not Enter." The sign made it clear that they didn't want anyone around. That wasn't going to
                        stop Jack. Jack always lived with the notion that signs were mere suggestions, not actually
                        absolute rules. That's why the moment Jack looked at the "Do Not Enter" sign, he walked past it
                        and onto their property.</p>
                    <ul>
                        <li>chapter</li>
                        <li>honey</li>
                        <li>homework</li>
                        <li>potato</li>
                        <li>marketing</li>
                        <li>topic</li>
                        <li>reception</li>
                        <li>basket</li>
                        <li>indication</li>
                        <li>engine</li>
                        <li>judgment</li>
                        <li>feedback</li>
                        <li>significance</li>
                    </ul>
                </div>
                <div class="col-sm-offset-6 text-center"><a href="https://doi.org/10.1093/jnci/djy156"
                        target="_new"><img alt="Screenshot" src="/img/msk-JNCI.png"></a><br>
                    <img alt="Article Image" class="mb32 mb-xs-16" src="/img/tat.png" style="width:50%">
                </div>
            </div>
            <div class="col-sm-12">
                <p>Below are the spectrum and number of SNVs, Indels, CNV, and fusions detected by the ctDx Lung assay
                    in the first 210 NSCLC patients.</p>
            </div>
        </div>
        <div class="row mb8 mb-xs-24">
            <div id="MSKContainer" width="100%" style="margin-top: 0px;">
                <div id="dataWindow"></div>
            </div>
    </section>

    <section class="page-title page-title-3 image-bg overlay parallax">
        <div class="background-image-holder">
            <img alt="Background Image" class="background-image" src="/img/squareFusion.jpg"
                style="background-size: 800px 533px;">
        </div>
        <div class="container">
            <div class="row">
                <div class="col-sm-12 text-center">
                    <h3 class="uppercase mb0">Fusions</h3>
                </div>
            </div>

        </div>
    </section>
    <section>
        <div class="container">
            <div class="row mb8 mb-xs-24">
                <div class="col-sm-8 col-md-8 col-md-offset-1">
                    <h2 class="color-primary">Fusion Detection</h2>
                    <p>Researchers at the <b>Vanderbilt University Medical Center</b> used the Resolution ctDx Lung
                        assay in the study &quot;<a href="https://doi.org/10.1016/j.jtho.2019.08.003"
                            target="_new">Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor
                            DNA in Patients With ALK+ Lung Cancer</a>&quot; (<a
                            href="https://doi.org/10.1016/j.jtho.2019.08.003"
                            target="_new">doi.org/10.1016/j.jtho.2019.08.003</a>) to detect ALK gene fusions. The
                        detected EML4-ALK rearrangments are plotted on the interactive graph below. The ctDx platform
                        detects gene fusions / rearrangements without <i>a prior</i> knowledge of breakpoint or gene
                        partner, resulting in the ability to not only capture canonical fusions, but also discover novel
                        fusion partners.
                    <p>
                </div>
                <div class="col-md-3">
                    <a href="https://doi.org/10.1016/j.jtho.2019.08.003" target="_new"><img alt="Screenshot"
                            src="/img/VCC_IASLC.png"></a>
                </div>
                <div class="row mb8 mb-xs-24">
                    <div id="fusionContainer" width="100%" style="margin-top: 0px;"></div>
                </div>
                <div class="row mb32 mb-xs-24">
                    <h6>
                        <center>Pan by dragging along the genomic coordinates. Zoom by double clicking or scroll wheel
                            over the genomic coordinates.</center>
                    </h6>
                </div>
            </div>
            <div class="row mb8 mb-xs-24">
                <div class="col-sm-8 col-md-8 col-md-offset-1">
                    <p>The <b>Dana-Farber Cancer Institute</b> compared the Resolution ctDx Lung Assay against Guardant
                        Health's Guardant360&reg; assay in the detection of the more challenging oncogenic gene fusions.
                        The resulting paper, <i><a href="https://doi.org/10.1016/j.lungcan.2019.06.004"
                                target="_new">Sensitivity of next-generation sequencing assays detecting oncogenic
                                fusions T in plasma cell-free DNA</a></i> (<a
                            href="https://doi.org/10.1016/j.lungcan.2019.06.004"
                            target="_new">doi.org/10.1016/j.lungcan.2019.06.004</a>) </p>
                    <p><i>Results: </i>Of 16 patients assayed known to harbor an ALK, ROS1, or RET in tumor, G360
                        detected fusions in 7 cases, Resolution ctDx Lung detected fusions in 13 cases, and 3 cases were
                        detected by neither. Of the 7 fusions detected by both assays, G360 reported lower mutant
                        allelic fractions (AF). In cases missed by G360, tumor derived TP53 mutations were often
                        detected confirming presence of tumor DNA. Raw sequencing data showed that inverted or
                        out-of-frame variants were overrepresented in cases detected using ctDx Lung but not by G360.
                    </p>

                </div>
                <div class="col-md-3">
                    <a href="https://doi.org/10.1016/j.lungcan.2019.06.004" target="_new"><img alt="Screenshot"
                            src="/img/DFCI_Lung_Cancer.png"></a>
                </div>
            </div>
            <div class="row">
                <div class="col-sm-11 col-md-11 col-md-offset-1 text-center">
                    <img alt="Article Image" class="mb0" src="/img/Supplee_et_al_fusions.png" style="width:95%"><br>
                    <small class="text-muted">Supplee et al. <i>Lung Cancer</i> 2019;134:96-99</small>
                </div>
            </div>
    </section>
</div>
</div>

</div>

<?php
footer('
<script src="https://d3js.org/d3.v4.min.js" type="text/javascript"></script>
<script src="/js/bootstrap.popover.js"></script>
<script src="/js/msk.ob.js"></script>
<script src="/js/fusion_jto.ob.js"></script>
');